Strategic merger Obalon merged with ReShape Lifesciences in early 2021, creating a larger platform in weight loss technologies. Sales teams should target combined entity for cross-sell opportunities in gastric balloon solutions, post-merger integration services, and expanded distribution.

Clinical collaboration The company emphasizes engineering-driven development with clinician collaboration. Focus sales outreach on partnerships for co-development,Clinical feedback programs, and interoperability testing to shorten time-to-market for new devices.

Regulatory interest Historical and ongoing attention from securities law matters around leadership and mergers presents a window for building trust through transparent pilot programs, customer due diligence, and compliant procurement processes to win enterprise contracts.

Mid-market footprint Current employee range and revenue indicate a small-to-mid sized operation with potential for scalable solutions. Upsell opportunities exist for modular manufacturing services, supply chain optimization, and maintenance contracts suitable for mid-size health-tech buyers.

Financial runway Funding levels (~$17M) and modest revenue suggest a need for cost-effective, high-ROI solutions. Position value around total cost of ownership reductions, automated testing, and rapid deployment of gastric balloon technologies to attract budget-conscious buyers.